Adelaide Research & Scholarship: Search

Search

Results 21-30 of 102 (Search time: 0.005 seconds).

previous
1
2
3
4
5
6
...
11
next

Item hits:

Preview	Issue Date	Title	Author(s)
	1995	Effect of dietary N-3 fatty-acids on human monocyte (MC) tumor-necrosis-factor-alpha (TNF-alpha) and interleukin-1-beta (IL-1-beta) synthesis	James, M.; Mantzioris, E.; Caughey, G.; Cleland, L.; Gibson, R.; Experimental Biology '95 (9 Apr 1995 - 13 Apr 1995 : Atlanta, Georgia)
	2014	Relationship between plasma omega-3 fatty acids and clinical outcomes in recent onset rheumatoid arthritis	Proudman, S.; Cleland, L.; Lee, A.; Wechalekar, M.; Metcalf, R.; Sullivan, T.; Spargo, L.; James, M.; Australian Rheumatology Association 55th Annual Scientific Meeting (17 May 2014 - 20 May 2014 : Hobart, Tasmania)
	1999	Effects of Tumor Necrosis Factor-a, Interleukin 1B, and Activated Peripheral Blood Mononuclear Cells on the Expression of Adhesion Molecules and Recruitment of Leukocytes in Rheumatoid Synovial Xenografts in SCID Mice	Proudman, S.; Cleland, L.; Mayrhofer, G.
	2012	Fish oil in rheumatoid arthritis: a randomised, double blind trial comparing high dose with low dose	Proudman, S.; Spargo, L.; Hall, C.; McWilliams, L.; Lee, A.; Rischmueller, M.; Gibson, R.; James, M.; Cleland, L.; Australian Rheumatology Association Annual Scientific Meeting (2012 : Canberra, A.C.T.)
	2014	Synovial fluid myeloid dendritic cells display important differences compared to monocyte-derived dendritic cells prepared in vitro	Moghaddami, M.; James, M.; Whittle, S.; Cleland, L.
	2014	A pilot study to assess the impact of patient, genetic and disease factors on response to the disease modifying anti-rheumatic drug leflunomide	Wiese, M.; Hopkins, A.; Spargo, L.; McWilliams, L.; O'Doherty, C.; Cleland, L.; Proudman, S.; Australian Rheumatology Association 55th Annual Scientific Meeting (17 May 2014 - 20 May 2014 : Hobart, Tasmania)
	2006	Fish oil: what the prescriber needs to know	Cleland, L.; James, M.; Proudman, S.
	2001	COX-2 inhibition and thrombotic tendency: a need for surveillance	Cleland, L.; James, M.; Stamp, L.; Penglis, P.
	2002	Considerations for the safe prescribing and use of COX-2-specific inhibitors	Barraclough, D.; Bertouch, J.; Brooks, P.; Brown, M.; Cleland, L.; Clemens, L.; Crowley, S.; Day, R.; DeJager, J.; Edmonds, J.; Fletcher, P.; Franks, G.; Harris, D.; Horowitz, J.; Johnston, M.; Kerr, S.; Littlejohn, G.; MacDonald, G.; McColl, G.; Sambrook, P.; et al.
	2006	Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia - Cost effectiveness and risk sharing	Wlodarczyk, J.; Cleland, L.; Keogh, A.; McNeil, K.; Perl, K.; Weintraub, R.; Williams, T.